Grid Therapeutics Closes Series B Financing Posted on April 26, 2018April 26, 2018, in News, Press Releases Read more
Grid Therapeutics Selected by the NCI’s NExT Program to Complete the IND Enabling Nonclinical Work for GT103 Posted on October 31, 2017October 31, 2017, in News, Press Releases Read more
Grid Therapeutics Collaborates with Catalent to Develop the First Human-Derived Antibody for the Treatment of Cancer Posted on October 31, 2017, in News, Press Releases Read more
Grid Therapeutics Closes Series A Financing Posted on September 20, 2017, in News, Press Releases Read more
Grid Therapeutics Signs Exclusive License to Develop a Novel Immuno-Oncology Antibody Posted on August 28, 2017, in News, Press Releases Read more
